Drug discovery for neglected diseases: Molecular target-based and phenotypic approaches

Journal of Medicinal Chemistry

Volumn 56, Issue 20, 2013, Pages 7719-7726

  Gilbert, Ian H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BENZIMIDAZOLE DERIVATIVE; BENZNIDAZOLE; CDC2 RELATED KINASE 3; DDD 85646; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROOROTATE DEHYDROGENASE; E 1224; EFLORNITHINE; ENZYME; ENZYME INHIBITOR; FEXINIDAZOLE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE; PIPERAZINE DERIVATIVE; POSACONAZOLE; PROTEIN N MYRISTOYLTRANSFERASE; PROTEIN N MYRISTOYLTRANSFERASE INHIBITOR; PTERIDINE REDUCTASE 1; PTERIDINE REDUCTASE 1 INHIBITOR; PYRAZOLE DERIVATIVE; SCYX 7158; STIBOGLUCONATE SODIUM; SULFONAMIDE; SURAMIN; TRYPANOTHIONE SYNTHASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE; HIGH THROUGHPUT SCREENING; HUMAN; KINETOPLASTIDA; LEISHMANIASIS; MALARIA; MOLECULARLY TARGETED THERAPY; MOUSE; NEGLECTED DISEASE; NONHUMAN; PARASITE; PHENOTYPE; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; TROPICAL DISEASE; TRYPANOSOMA BRUCEI; VALIDATION STUDY; X RAY CRYSTALLOGRAPHY;

ACYLTRANSFERASES; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEGLECTED DISEASES; PHENOTYPE; PROTOZOAN PROTEINS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 84886542459     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400362b     Document Type: Article

References (48)

1. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discovery 2006, 5, 993-996
2. Brun, R.; Don, R.; Jacobs, R. T.; Wang, M. Z.; Barrett, M. P. Development of novel drugs for human African trypanosomiasis Future Microbiol. 2011, 6, 677-691
3. Alsford, S.; Eckert, S.; Baker, N.; Glover, L.; Sanchez-Flores, A.; Leung, K. F.; Turner, D. J.; Field, M. C.; Berriman, M.; Horn, D. High-throughput decoding of antitrypanosomal drug efficacy and resistance Nature 2012, 482, 232-236
4. Barrett, M. P.; Gilbert, I. H. Targeting of toxic compounds to the trypanosome's interior Adv. Parasitol. 2006, 63, 125-183
5. Barrett, M. P.; Gilbert, I. H. Targeting of Toxic Compounds to the Trypanosomes Adv. Parasitol. 2006, 63, 126-183
6. Wilkinson, S. R.; Taylor, M. C.; Horn, D.; Kelly, J. M.; Cheeseman, I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 5022-5027
7. Sokolova, A. Y.; Wyllie, S.; Patterson, S.; Oza, S. L.; Read, K. D.; Fairlamb, A. H. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis Antimicrob. Agents Chemother. 2010, 54, 2893-2900
8. Hall, B. S.; Bot, C.; Wilkinson, S. R. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites J. Biol. Chem. 2011, 286, 13088-13095
9. Maya, J.; Cassels, B.; Iturriaga Vasquez, P.; Ferreira, J.; Faundez, M.; Iturriaga Vásquez, P.; Faúndez, M.; Galanti, N.; Ferreira, A.; Morello, A. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host Comp. Biochem. Physiol., Part A: Mol. Integr. Physiol. 2007, 146, 601-620
10. Dorlo, T. P. C.; Balasegaram, M.; Beijnen, J. H.; de Vries, P. J. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis J. Antimicrob. Chemother. 2012, 67, 2576-2597
11. Croft, S. L.; Coombs, G. H. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs Trends Parasitol. 2003, 19, 502-508
12. Frearson, J. A.; Wyatt, P. G.; Gilbert, I. H.; Fairlamb, A. H. Target assessment for antiparasitic drug discovery Trends Parasitol. 2007, 23, 589-595
13. Wyatt, P. G.; Gilbert, I. H.; Read, K. D.; Fairlamb, A. H. Target Validation: Linking Target and Chemical Properties to Desired Product Profile Curr. Top. Med. Chem. 2011, 11, 1275-1283
14. Brown, D. L.; Devadas, B.; Lu, H. F.; Nagarajan, S.; Zupec, M. E.; Freeman, S. K.; McWherter, C. A.; Getman, D. P.; Sikorski, J. A. Replacements for lysine in l -seryl- l -lysyl dipeptide amide inhibitors of Candida albicans myristoyl-CoA: Protein N -myristoyltransferase Bioorg. Med. Chem. Lett. 1997, 7, 379-382
15. Nagarajan, S. R.; Devadas, B.; Zupec, M. E.; Freeman, S. K.; Brown, D. L.; Lu, H. F.; Mehta, P. P.; Kishore, N. S.; McWherter, C. A.; Getman, D. P.; Gordon, J. I.; Sikorski, J. A. Conformationally constrained [ p -(omega-aminoalkyl)phenacetyl]- l -seryl- l -lysyl dipeptide amides as potent peptidomimetic inhibitors of Candida albicans and human myristoyl-CoA: Protein N -myristoyltransferase J. Med. Chem. 1997, 40, 1422-1438
16. Sikorski, J. A.; Devadas, B.; Zupec, M. E.; Freeman, S. K.; Brown, D. L.; Lu, H. F.; Nagarajan, S.; Mehta, P. P.; Wade, A. C.; Kishore, N. S.; Bryant, M. L.; Getman, D. P.; McWherter, C. A.; Gordon, J. I. Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: Protein N -myristoyltransferase: a new approach to antifungal therapy Biopolymers 1997, 43, 43-71
17. Devadas, B.; Freeman, S. K.; McWherter, C. A.; Kishore, N. S.; Lodge, J. K.; Jackson-Machelski, E.; Gordon, J. I.; Sikorski, J. A. Novel biologically active nonpeptidic inhibitors of myristoylCoA: Protein N -myristoyltransferase J. Med. Chem. 1998, 41, 996-1000
18. Devadas, B.; Freeman, S. K.; McWherter, C. A.; Kuneman, D. W.; Vinjamoori, D. V.; Sikorski, J. A. A chiral recognition element with an unusual size constraint affects the potency and selectivity for peptidomimetic inhibitors of Candida albicans myristoyl-CoA: Protein N -myristoyltransferase Bioorg. Med. Chem. Lett. 1996, 6, 1977-1982
19. Devadas, B.; Freeman, S. K.; Zupec, M. E.; Lu, H. F.; Nagarajan, S. R.; Kishore, N. S.; Lodge, J. K.; Kuneman, D. W.; McWherter, C. A.; Vinjamoori, D. V.; Getman, D. P.; Gordon, J. I.; Sikorski, J. A. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA: Protein N -myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity J. Med. Chem. 1997, 40, 2609-2625
20. Devadas, B.; Zupec, M. E.; Freeman, S. K.; Brown, D. L.; Nagarajan, S.; Sikorski, J. A.; McWherter, C. A.; Getman, D. P.; Gordon, J. I. Design and Syntheses of Potent and Selective Dipeptide Inhibitors of Candida Albicans Myristoyl-CoA-Protein N -Myristoyltransferase J. Med. Chem. 1995, 38, 1837-1840
21. Ebiike, H.; Masubuchi, M.; Liu, P. L.; Kawasaki, K.; Morikami, K.; Sogabe, S.; Hayase, M.; Fujii, T.; Sakata, K.; Shindoh, H.; Shiratori, Y.; Aoki, Y.; Ohtsuka, T.; Shimma, N. Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N -myristoyltransferase. Part 2 Bioorg. Med. Chem. Lett. 2002, 12, 607-610
22. Kawasaki, K.; Masubuchi, M.; Morikami, K.; Sogabe, S.; Aoyama, T.; Ebiike, H.; Niizuma, S.; Hayase, M.; Fujii, T.; Sakata, K.; Shindoh, H.; Shiratori, Y.; Aoki, Y.; Ohtsuka, T.; Shimma, N. Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N -myristoyltransferase. Part 3 Bioorg. Med. Chem. Lett. 2003, 13, 87-91
23. Masubuchi, M.; Ebiike, H.; Kawasaki, E.; Sogabe, S.; Morikami, K.; Shiratori, Y.; Tsujii, S.; Fujii, T.; Sakata, K.; Hayase, M.; Shindoh, H.; Aoki, Y.; Ohtsuka, T.; Shimma, N. Synthesis and biological activities of benzofuran antifungal agents targeting fungal N -myristoyltransferase Bioorg. Med. Chem. 2003, 11, 4463-4478
24. Masubuchi, M.; Kawasaki, K.; Ebiike, H.; Ikeda, Y.; Tsujii, S.; Sogabe, S.; Fujii, T.; Sakata, K.; Shiratori, Y.; Aoki, Y.; Ohtsuka, T.; Shimma, N. Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N -myristoyltransferase. Part 1 Bioorg. Med. Chem. Lett. 2001, 11, 1833-1837
25. Ebara, S.; Naito, H.; Nakazawa, K.; Ishii, F.; Nakamura, M. FTR1335 is a novel synthetic inhibitor of Candida albicans N -myristoyltransferase with fungicidal activity Biol. Pharm. Bull. 2005, 28, 591-595
26. Yamazaki, K.; Kaneko, Y.; Suwa, K.; Ebara, S.; Nakazawa, K.; Yasuno, K. Synthesis of potent and selective inhibitors of Candida albicans N -myristoyltransferase based on the benzothiazole structure Bioorg. Med. Chem. 2005, 13, 2509-2522
27. Price, H. P.; Menon, M. R.; Panethymitaki, C.; Goulding, D.; McKean, P. G.; Smith, D. F. Myristoyl-CoA: Protein N -myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites J. Biol. Chem. 2003, 278, 7206-7214
28. Panethymitaki, C.; Bowyer, P. W.; Price, H. P.; Leatherbarrow, R. J.; Brown, K. A.; Smith, D. F. Characterization and selective inhibition of myristoyl-CoA: Protein N -myristoyltransferase from Trypanosoma brucei and Leishmania major Biochem. J. 2006, 396, 277-85
29. Price, H. P.; Guther, M. L. S.; Ferguson, M. A. J.; Smith, D. F. Myristoyl-CoA: Protein N -myristoyltransferase depletion in trypanosomes causes avirulence and endocytic defects Mol. Biochem. Parasitol. 2010, 169, 55-58
30. Brand, S.; Cleghorn, L. A.; McElroy, S. P.; Robinson, D. A.; Smith, V. C.; Hallyburton, I.; Harrison, J. R.; Norcross, N. R.; Spinks, D.; Bayliss, T.; Norval, S.; Stojanovski, L.; Torrie, L. S.; Frearson, J. A.; Brenk, R.; Fairlamb, A. H.; Ferguson, M. A.; Read, K. D.; Wyatt, P. G.; Gilbert, I. H. Discovery of a novel class of orally active trypanocidal N -myristoyltransferase inhibitors J. Med. Chem. 2012, 55, 140-152
31. Brenk, R.; Schipani, A.; James, D.; Krasowski, A.; Gilbert, I. H.; Frearson, J. A.; Wyatt, P. G. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases ChemMedChem 2008, 3, 435-444
32. Frearson, J. A.; Brand, S.; McElroy, S. P.; Cleghorn, L. A. T.; Smid, O.; Stojanovski, L.; Price, H. P.; Guther, M. L. S.; Torrie, L. S.; Robinson, D. A.; Hallyburton, I.; Mpamhanga, C. P.; Brannigan, J. A.; Wilkinson, A. J.; Hodgkinson, M.; Hui, R.; Qiu, W.; Raimi, O. G.; Van Aalten, D. M. F.; Brenk, R.; Gilbert, I. H.; Read, K. D.; Fairlamb, A. H.; Ferguson, M. A. J.; Smith, D. F.; Wyatt, P. G. N -Myristoyltransferase inhibitors as new leads to treat sleeping sickness Nature 2010, 464, 728-732
33. Chagas Disease; BIO Ventures for Global Health: Washington, DC, 2011; http://www.bvgh.org/Biopharmaceutical-Solutions/Global-Health-Primer/Diseases/ cid/ViewDetails/ItemID/1.aspx.
34. Wells, T. N.; Alonso, P. L.; Gutteridge, W. E. New medicines to improve control and contribute to the eradication of malaria Nature Rev. Drug Discovery 2009, 8, 879-891
35. Coteron, J. M.; Marco, M.; Esquivias, J.; Deng, X.; White, K. L.; White, J.; Koltun, M.; El Mazouni, F.; Kokkonda, S.; Katneni, K.; Bhamidipati, R.; Shackleford, D. M.; Angulo-Barturen, I.; Ferrer, S. B.; Jimenez-Diaz, M. B.; Gamo, F. J.; Goldsmith, E. J.; Charman, W. N.; Bathurst, I.; Floyd, D.; Matthews, D.; Burrows, J. N.; Rathod, P. K.; Charman, S. A.; Phillips, M. A. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential J. Med. Chem. 2011, 54, 5540-5561
36. Phillips, M. A.; Rathod, P. K. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy Infect. Disord. Drug Targets 2010, 10, 226-239
37. Sienkiewicz, N.; Ong, H. B.; Fairlamb, A. H. Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in mice Mol. Microbiol. 2010, 77, 658-671
38. Mpamhanga, C. P.; Spinks, D.; Tulloch, L. B.; Shanks, E. J.; Robinson, D. A.; Collie, I. T.; Fairlamb, A. H.; Wyatt, P. G.; Frearson, J. A.; Hunter, W. N.; Gilbert, I. H.; Brenk, R. One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening J. Med. Chem. 2009, 52, 4454-4465
39. Spinks, D.; Ong, H. B.; Mpamhanga, C. P.; Shanks, E. J.; Robinson, D. A.; Collie, I. T.; Read, K. D.; Frearson, J. A.; Wyatt, P. G.; Brenk, R.; Fairlamb, A. H.; Gilbert, I. H. Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductase 1 ChemMedChem 2011, 6, 302-308
40. Sienkiewicz, N.; Jarosławski, S.; Wyllie, S.; Fairlamb, A. H. Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes Mol. Microbiol. 2008, 69, 520-533
41. Wyllie, S.; Oza, S. L.; Patterson, S.; Spinks, D.; Thompson, S.; Fairlamb, A. H. Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods Mol. Microbiol. 2009, 74, 529-540
42. Spinks, D.; Torrie, L. S.; Thompson, S.; Harrison, J. R.; Frearson, J. A.; Read, K. D.; Fairlamb, A. H.; Wyatt, P. G.; Gilbert, I. H. Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors ChemMedChem 2012, 7, 95-106
43. Torrie, L. S.; Wyllie, S.; Spinks, D.; Oza, S. L.; Thompson, S.; Harrison, J. R.; Gilbert, I. H.; Wyatt, P. G.; Fairlamb, A. H.; Frearson, J. A. Chemical Validation of Trypanothione Synthetase J. Biol. Chem. 2009, 284, 36137-36145
44. Doerig, C. Protein kinases as targets for anti-parasitic chemotherapy Biochim. Biophys. Acta: Proteins Proteomics 2004, 1697, 155-168
45. Hassan, P.; Fergusson, D.; Grant, K. M.; Mottram, J. C. The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana Mol. Biochem. Parasitol. 2001, 113, 189-198
46. Grant, K. M.; Dunion, M. H.; Yardley, V.; Skaltsounis, A. L.; Marko, D.; Eisenbrand, G.; Croft, S. L.; Meijer, L.; Mottram, J. C. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity Antimicrob. Agents Chemother. 2004, 48, 3033-3042
47. Swinney, D. C.; Anthony, J. How were new medicines discovered? Nature Rev. Drug Discovery 2011, 10, 507-519
48. Hopkins, A. L. Network Pharmacology: the next paradigm in drug discovery Nature Chem. Biol. 2008, 4, 682-690